Morton Grossman , the father of modern gastrointestinal endocrine physiology, was truly one of the giants of the last century in gastrointestinal research. Dr Grossman's appointment in 1955 as chief of gastroenterology at the Wadsworth VA Medical Center in Los Angeles was a major turning point in his career. From 1955 From until 1962 , he ran the section and trained clinical gastroenterologists, all the while continuing his research. He was one of the first scientists appointed to the newly created Senior Medical Investigator program at the VA and was also professor of medicine and physiology at the UCLA School of Medicine.
In 1973, Dr Grossman learned that the National Institutes of Health intended to fund a center for the study of peptic ulcer disease. Almost single-handedly he organized the Wadsworth-UCLA and Dallas GI groups to submit a proposal, which was funded. Thus, in 1974 Dr Grossman became the first director of the Center for Ulcer Research and Education (CURE), which served as a prototype for the Digestive Diseases Research Core Center Program at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
During his life, Dr Grossman authored 400 articles. He trained a generation of fellows and scientists from all parts of the world. Many of them went on to successful research careers and to hold positions of distinction as heads of departments of gastroenterology, surgery, and physiology. His major contributions lay in defining the secretory mechanisms of the stomach and pancreas and the actions of regulatory gastrointestinal peptides. Dr Grossman set uncompromising standards for scientific validity and accuracy of reporting. In 1979 he was presented the Friedenwald Medal from the American Gastroenterological Association in recognition of his accomplishments.
His friends and colleagues will most remember his curiosity, his encyclopedic memory, the breadth of his interests and his energy in pursuing them, his intelligence, his perfectionism, his fairness, his wisdom, his integrity, his devotion, and his kindness.
The Grossman Distinguished Lectureship was established in 1989 to honor the memory and accomplishments of Dr Grossman. Previous speakers have all been distinguished, world-renowned scientists, including eight Nobel laureates. The 2015 Grossman Lecture will be given by Hans Clevers, president of the Royal Netherlands Academy of Arts and Sciences.
Over the last decade, few scientists have had as significant an impact on digestive disease research as Dr Clevers. Over a decade ago, Dr Clevers identified a transcription factor TCF1 as a key transcriptional effector protein of the Wnt signaling pathway. His discovery had a major impact on understanding this important pathway in metazoan development. More importantly his findings identified a missing link toward understanding how adenomatous polyposis coli (APC) mutations and b-catenin give rise to colorectal cancer.
With the tools he developed for studying Wnt signaling, Dr Clevers recognized that self-renewing cells at the base of intestinal crypts showed highly active Wnt signaling. This critical observation lead to the discovery of a seven transmembrane domain receptor, leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), as both a Wnt target gene and a marker of intestinal stem cells (ISC). Although the existence of a pluripotent intestinal stem had been proposed for decades, it remained elusive for study because there were no known markers.
In a series of classic experiments, Clevers and his colleagues established that LGR5-expressing cells fulfilled the properties of the long-postulated self-renewing intestinal stem cell. His discoveries and ongoing work have triggered an avalanche of information from his laboratory and many others about the ISC as an adult stem cell, the biology of the stem cells and their niche, the functional role of LGR5 as an R-spondin receptor, and the ability to propagate stem cells in organoid cultures. As a result of his seminal work, the ability to study stem cells has evolved from experiments that could never be done, to a wellspring of new knowledge that has our advanced understanding of the gastrointestinal tract.
Gastrointestinal Oncology Section
William M. Grady, MD, AGAF, and Rhonda F. Souza, MD, AGAF
The Gastrointestinal Oncology section (GIONC) focuses on research in biomarkers, colon cancer screening, cancer chemoprevention, and tumor biology (colorectal cancer, esophageal cancer, pancreatic cancer, and gastric cancer). The GIONC section has played a key role in the multisociety ASCO/AGA/SSO/ASTRO GI Cancers Symposium that is held annually in January, where section members are key leaders at this meeting through their roles as members of the program committee and steering committee, and as invited speakers. Additionally, the strength of the GIONC section comes from its ability to address and highlight broad themes in oncology that pertain to multiple cancer types, not only those restricted to a single organ site.
Research Fora
GIONC has developed a program for DDW 2015 that covers advances in some of the most dynamic areas of gastrointestinal cancer research. Twelve research fora span basic and translational research on a number of exciting topics.
Saturday, May 16, 2015: "Gastric Neoplasms: Precursors, Biology, Diagnosis and Therapy," "Biomarkers for Detection, Treatment, and Prognosis of GI Cancers," "Therapy for GI Cancers: Translational and Targeted Approaches," "Tumor Biology and Tumor Microenvironment," "Stem Cell Biology and Cancer," and "Inflammation, Tumor Microenvironment, and Pancreatic Carcinogenesis."
Sunday, May 17, 2015: "Esophageal Neoplasms: Mechanisms of Carcinogenesis," "Cancer Susceptibility and Familial Cancer Syndromes," and "Molecular Pathways in Carcinogenesis, Angiogenesis, and Metastasis." 
Distinguished Abstract Plenary
Another highlight of DDW 2015 is the GIONC distinguished abstract plenary session being held on Monday, May 18, 2015. This session will feature advances in GI cancer therapies and biomarkers by showcasing some of the best posters submitted to our section this year.
Symposia
The GIONC section will also be hosting several symposia spanning clinical, basic, and translational research. Growth, Development, and Child Health Section Alessio Fasano, MD, and Noah F. Shroyer, PhD
The Growth, Development and Child Health (GDCH) section is the home for pediatrics and developmental biology within the AGA. The membership of GDCH has the most diverse range of digestive health interests within the AGA, representing the interests of pediatrics within all digestive organ systems as well as basic science related to growth, development, and pediatrics.
GDCH received 129 abstracts for DDW 2015, of which 36 (28%) were accepted for oral presentations and 79 (61%) were accepted as posters. One abstract entitled "Villus Morphogenesis Re-examined: Unique Cell Division Carve Out Intestinal Villi" was selected for oral presentation as part of the AGA Basic Science Plenary. These numbers are quite similar to the overall number of abstracts submitted over the past 5 years. For DDW 2015, GDCH is sponsoring 10 oral sessions and four poster sessions.
Research Fora
Seven research fora include oral presentations selected from the abstracts:
Saturday 
Poster Sessions
Finally, GDCH is sponsoring four poster sessions: "Pediatric IBD," "Pediatric Functional and Motility Disorders," "Clinical Pediatric Gastroenterology," and "Pediatric Translational Research."
Immunology, Microbiology, and Inflammatory Bowel Diseases Section
Edward V. Loftus Jr., MD, AGAF, and Mark S. Silverberg, MD, PhD DDW continues to be the preeminent scientific meeting for the field of inflammatory bowel diseases (IBD). The Immunology, Microbiology and Inflammatory Bowel Diseases (IMIBD) section is the largest of the AGA Council sections and continues to attract the best scientific work of the year. There are numerous topic descriptors for abstract submission that cover the spectrum of basic and translational science related to IMIBD in addition to clinical science. The section covers important major scientific topics such as innate and adaptive immunity, genetics and the microbiome, animal models of IBD, mucosal immunology, epithelial cell biology, and stem cells. DDW is an outstanding opportunity for scientists to get state-of-the-art knowledge in a specific field of interest in addition to a well-rounded update in the field.
For the 2015 meeting there were 1096 abstracts submitted, with only 9% selected for oral presentation and about 60% accepted for poster presentation. This was a particularly competitive year with roughly 30% of the submitted abstracts rejected. Although it is not necessarily ideal to have such a high rejection rate, this does result in higher quality presentations at the meeting. We encourage all members from the scientific community interested in the IMIBD topics to attend DDW this year.
Research Fora
Some of the most exciting basic and translational highlights of the IMIBD section's 17 research fora are included here.
These basic research sessions are a must-see at DDW 2015. On Saturday, May 16, 2015, a research forum addressing progress in developing novel therapeutics using animal models will take place. As the science evolves from IBD gene identification to gene function and biology, a Research Forum on Sunday, May 17, 2015, will include presentations that describe new genetic discoveries as well as some breakthroughs in understanding the function of known IBD gene variants. There will also be a mini-state-ofthe-art lecture provided to summarize the current and future state of affairs in IBD genetics. Other research fora at DDW will focus on cytokines and receptors, pre and probiotics, and stem cell biology. 
Distinguished Abstract Plenary
The IMIBD distinguished abstract plenary session on Monday, May 18, 2015, will contain presentations on a largescale study examining the composition of the fecal microbiome in healthy first-degree relatives of Crohn's disease patients and the role of RAC proteins in intestinal inflammation.
Intestinal Disorders Section
Nicholas O. Davidson, MD, AGAF and Wayne I. Lencer, MD, AGAF
The Intestinal Disorders (ID) section is the fourth largest section of AGA Council, receiving 416 abstracts in 2015, of which 53 (13%) were accepted for oral presentation and 258 (62%) were accepted for poster presentation. These figures compare favorably with historical trends for 2012-2014 (oral, range: 13%-17%; poster, range: 57%-63%).
The ID section members' interests span a range of areas, embracing disease focused (celiac disease, radiation-and chemotherapy-induced injury) and pathway-driven processes (diarrhea and malabsorption, host-microbial interactions, epithelial transport) as well as translational interests that include epithelial functions and junctions in wound repair, nutrient and lipid processing, and antigen sensing/processing in innate immunity. In addition, the ID section has promoted interest in the use of isolated enteroids and organoids for the study of intestinal disease, reflecting the emerging interest in stem cell biology.
Research Fora
For DDW 2015, the ID section is sponsoring eight research fora, which are aggregated around abstract submissions reflecting a general theme. Of these eight research fora, there is an equal distribution of basic and translational content. 
Distinguished Abstract Plenary
In addition to these abstract-driven research fora, there is a distinguished abstract plenary session (Saturday, May 16, 2015) at which we will present the Research Mentor Award to Jerrold Turner, MD, PhD. The distinguished abstract plenary session reflects a range of high-impact abstracts including both basic and clinical topics.
Symposia
The ID section is also sponsoring a research symposium (Saturday, May 16, 2015) focused on "Next Generation Sequencing: Opportunities for Research and Practice." This symposium will feature three experts who will discuss findings that include "Single-Cell PCR Using Fluidigm Technology" (Scott Magness); "Functional Heterogeneity of T-Cell Receptors at the Single Cell Level" (Arnold Han); and "Next Generation Sequencing in Colorectal Cancer/Polyposis Syndromes" (Ian Tomlinson). This research symposium will allow attendees to gain detailed insight into advances in single-cell transcriptomics and to understand how advances in sequencing technology are transforming clinical practice by facilitating subclassification of disease phenotypes.
Finally, the ID section is sponsoring two clinical symposia and one translational symposium.
The translational symposium (Saturday, May 16, 2015 ) is organized around "Xenobiotics, Microbiota, and Intestinal Disease" and features three experts who will discuss findings that include "Gut Reactions: Understanding Drug Metabolism by the Human Microbiota" (Emily Balskus); "Xenobiotics and Intestinal Injury (Axel Behrens); and "Intestinal Efflux Transporters and Multidrug Resistance in Inflammation" (Elke Cario). This translational symposium will allow attendees to gain perspective into how the microbiota interact with and influence drug metabolism.
The first clinical symposium on Monday, May 18, 2015, is organized around "Radiation Injury, Intestinal Failure, and Rehabilitation" and features three experts who will discuss the current state of the art in this difficult management problem. Their topics will include "Radiation Enteropathy: Clinical Perspectives for the Future" (Jerviose Andreyev); "Intestinal Rehabilitation" (Donald F. Kirby); and "Managing Sepsis and Infections in Patients with Intestinal Failure" (Georg Lamprecht). This symposium will provide attendees with perspectives and insights from European and U.S. centers of excellence, including very practical details on preventing and managing important complications and outlining future directions for the field.
The second clinical symposium on Monday, May 18, 2015, is organized around "Celiac Disease: Causes and Dilemmas" and features an international group of experts who will discuss topics including "Why Is Celiac Disease on the Rise and Can It Be Prevented?" (Anneli Iversson); "Suspected Celiac Disease: How to Secure a Diagnosis" (Benjamin Lebwohl); "What to Do With Persistent Symptoms and/or Partial Recovery?" (Joseph A. Murray); and "How to Diagnose and Manage Refractory Celiac Disease?" (Chris J. Mulder). This symposium will provide attendees a granular understanding of the key challenges in the epidemiology, diagnosis, and management of celiac disease.
Liver and Biliary Section
Jayant A. Talwalkar, MD, MPH, and Kenneth E. Sherman, MD, PhD Membership in the Liver and Biliary (LB) section has seen a slight increase in the past few years. As of May 2014, the section counts 5038 members, which represents a 3% increase in membership since 2010. Domestic members comprise 65% of the section; international members comprise 18% of the base. More than 14% of the members are trainees (domestic and international), which represents one of the highest proportions of trainee members among all council sections. Nurse practitioners and practice managers comprise just 3% of the membership. Consistent with other sections, the large majority of Liver and Biliary members affiliate with multiple sections; including Clinical Practice; Esophageal, Gastric and Duodenal Disorders; and Intestinal Disorders.
Research Fora
The LB section is sponsoring two research fora, which will have oral abstract presentations centered on general themes. These include: A joint global clinical symposium sponsored by the LB and Clinical Practice sections will be held on Tuesday, May 19, 2015, and will focus on the "Implementation of the Affordable Care Act and the Practice of Gastroenterology and Hepatology." Topics include "Current Concepts in Provider and System-Based Quality of Care Measurement "(Spencer Dorn); "Impact of Health Insurance Coverage from Exchanges on Out-of-Pocket Costs for GI Services" (Joel Brill); and "Price Transparency, Narrow Networks and Academic Health Centers" (Mark McClellan). This novel and timely symposium will be of great interest to attendees given the recent changes in health-care reform and what effects this will have on the practice of gastroenterology and hepatology.
State of the Art
Last but not least, the LB section will once again host the Charles S. Lieber State-of-the-Art Lecture on Sunday, May 17, 2015. The invited speaker for the Lieber Lecture is Dr Scott Friedman, who will present on "NASH: The Convergence of Inflammation, Fat, and Fibrosis and the Path to Treatment."
Neurogastroenterology and Motility Section
Pankaj J. Pasricha, MD, and Satish S. C. Rao, MD, PhD, AGAF There has never been a better time in terms of research and clinical advances in neurogastroenterology and motility (NGM). Often considered a "black box" in our specialty, the last few years have seen a flurry of basic science discoveries, novel therapeutic targets, refinement of diagnostic techniques, and several promising new drugs in the pipeline. At this DDW, the NGM section menu reflects this spectrum of innovation and the excitement around it.
Research Fora
There are many exciting fora where cutting-edge science will be discussed. 
Distinguished Abstract Plenary
The culmination of these exciting research fora is the NGM plenary session on Monday, May 18, 2015, where the attendees will be able to listen to firsthand presentations of the best abstracts highlighting the most significant advances from bench to translational to clinical neurogastroenterology and motility. In addition, they will witness the presentation of the Research Mentor Award for 2015 to Michael Camilleri, MD, AGAF.
Symposia
In addition to the research fora at DDW 2015, the NGM section is sponsoring research, translational, and clinical symposia that feature expert invited speakers.
The research symposium on Saturday, May 16, 2015, will be "NGM Cutting-Edge: New Roles for Old Cells." We are bringing in experts from outside of gastroenterology to learn from them how their groundbreaking research can inform us about possible directions we need to take and where the next generation of discoveries will come from. Thus, Isaac Chiu will talk to us about "How Sensory Neurons Sense Bacteria" and Milena Bogunovic will educate us about "Macrophages and GI Motility." Finally Kenton Sanders will discuss the emerging story of "Fibroblasts and Gut Motility." This year's translational symposium will be on Monday, May 18, 2015, and will focus on "Making Research Work for Patients-What Is in the Pipeline?" Here we will go to the next step in translation-learning about new and emerging diagnostic and therapeutic targets for functional and motility disorders. We will also assess the current state of our knowledge about biomarkers for irritable bowel syndrome and hear about new directions for microbiota manipulation for clinical benefit. Our topics and speakers include "Purinergic Drugs for Management of GI Disorders" (Fievos L. Christofi); "MicroRNAs, Genomics, and IBS: What Is the Link and Are We Any Closer to Finding Biomarkers?" (John W. Wiley); and "Therapeutic Modulation of Gut Microbiota" (Purna C. Kashyap).
Lastly, our global clinical symposium on Saturday, May 16, 2015, will address "Developing Targeted Drug Therapy for GI Disease." An idea or discovery is only important if patients have access to it-in other words, if it makes it to the market. In this session, the audience will learn about the trials and travails of bringing forward new drugs and developing new targets for symptomatic relief or cure. We will also listen to the perspective of Big Pharma on GI disorders as a therapeutic area and what it perceives as the scientific or market barriers to drug development in gastroenterology. This will feature the following talks: In recent years, DDW programming by the Obesity, Metabolism and Nutrition (OMN) section has emphasized subject areas that have appealed to a majority of meeting attendees, especially those affiliated not only with the OMN section but also other sections with which we share common interests, as reflected by our strong participation in cross-sectional programming. A major emphasis on obesity and nutritional and metabolic disorders was solidified by a section name change in 2013 to "Obesity, Metabolism and Nutrition," reflecting a research and clinical focus on this spectrum of major health problems. New programming has included fora and symposia highlighting related topics, including bariatric surgery and its impact on nutritional status, GI neuroendocrinology and metabolism, new and innovative endoscopic and other treatments of obesity and diabetes, fatty liver disease, GI regulation of energy balance, weight and metabolic function, microbiota and metabolic regulation, and nutrition and metabolism across the life cycle. Nutritional support in all of its forms used in the management of a variety of diseases-including obesity, intestinal failure, and inflammatory bowel disease as well as nutrient absorption and metabolism-have also continued to be the focus of OMN programming. The OMN section also has endeavored to strike a balance between basic research to shed light on disease mechanisms, including preclinical studies to develop new therapies, and clinical and translational research to better describe disease phenotypes and test new therapeutic approaches.
The OMN section received 139 abstracts in 2014 and 137 in 2015, higher numbers than the previous years. In 2015, 25 (23%) were accepted for oral presentations, and 82 (77%) were accepted for poster presentations.
Research Fora
For DDW 2015, the OMN section is sponsoring four research fora, each with a focused theme and encompassing basic and translational research. These include:
Symposia
In addition to these research fora, the OMN section will be sponsoring four themed symposia.
Saturday, May 16, 2015: "Nutrition, Epigenetics, and Metabolic Imprinting." This research symposium will feature three experts discussing the role of early environmental and nutritional exposures in epigenetic alteration and metabolic imprinting, which have important implications for obesity and metabolic risk later in life. 
Research Fora
Saturday, May 16, 2015: "Pancreatic Cystic Neoplasms and Cancer" examines the diagnostic and prognostic value of biomarkers for pancreatic cancer and the emerging epidemiologic and cost data that impact evaluation and monitoring strategies for branch duct intraductal papillary mucinous neoplasms (IPMNs).
Sunday, May 17, 2015: "Pathobiology of the Pancreas" addresses the intrapancreatic effects of transforming growth factor b (TGF-b) on pain behavior; the relationships among dietary fat, body mass index, and severity of acute pancreatitis; how a defective unfolded protein response promotes pancreatic cell injury and gland fibrosis; and how pancreatic tumorigenic behavior is fostered by pancreatic stellate cell exosomes and by tumor BclxL expression.
Symposia
The PAN section is cosponsoring an exciting research symposium on Monday, May 18, 2015: "Irritant Sensing in the Gut: New Pathways to Visceral Pain of Digestive Diseases."
The clinical symposium on Saturday, May 16, 2015, will be on "Clinical Targeting of Stellate Cells and Autophagy in Pancreatic Cancer: Hope for Patients or Potential Disaster?" Experts in the field will focus on evolving clinical treatment targets for pancreatic cancer, and the paradoxical pro-and antineoplastic effects of stellate cells and inhibition of autophagy on pancreatic cancer.
On Saturday, May 16, 2015, PAN will host a global translational symposium on "Epigenetics: A New Paradigm for Complex GI Diseases," which will introduce an exciting new paradigm for understanding, diagnosing, and treating complex GI diseases, including pancreatitis, fibrosis, and cancer.
Sunday, May 17, 2015, will bring "Are Biomarkers Practical for Early Detection and Prognosis of Pancreatic Cancer?" Here, experts will review definitions for high-risk groups and early detection methods; screening and genetic testing; molecular biomarkers for early detection of pancreatic cancer; and current and future options for preventing pancreas cells with common Kras mutations from progressing to cancer.
Other Events
Beyond the research fora and symposia, there are plenty of other exciting events happening in the PAN section at DDW 2015.
Highlights of the poster sessions include "Pancreatic Genetics, Epigenetics and Pathobiology of the Pancreas" and "Pancreatic Cancer Risk Factors, Biomarkers and Diagnosis" on Saturday, May 16, 2015, and "Pancreatitis: Inflammation, Fibrogenesis, and Immunology" on Tuesday, May 19, 2015.
On Sunday, May 17, 2015, do not miss the AGA Focused Research Roundtable on "Insights Into Acinar Cells and Pancreatitis" featuring Dr Fred Gorelick who will discuss relevant basic research abstracts submitted to DDW 2015. At noon, join Dr Steven Pandol for a DDW Meet the Investigator Luncheon entitled "Emerging Bench to Bedside Treatments of Acute Pancreatitis." In the afternoon, attend the AGA/ASGE Presidential Plenary.
Monday, May 18, 2015, brings more PAN events. At noon, join Dr Roger Liddle for a DDW Meet the Investigator Luncheon entitled "Neurogenic Inflammation and Pain in the Pancreas." Also attend the distinguished abstract plenary session, which features top abstracts and presenters reporting key transcription factors responsible for pancreatic regeneration after injury, how pharmacologic inhibition of TGF-b reverses pancreatic fibrosis, novel imaging techniques to understand pancreatic microenvironment in pancreatic intraepithelial neoplasia (PanIN) development and gut permeability in pancreatitis, and the predictive value of K-Ras biomarkers for pancreatic cancer.
Finally, Tuesday May 19, 2015, brings the "ASGE/AGA Update on Pancreatic Cancer Screening," which will review the diagnostic and/or prognostic value of biomarkers for pancreatic cancer and will highlight other methods for riskstratifying pancreatic cancer and cancer precursor lesions.
Regulatory Peptides, Cell Signaling, and Molecular Biology Section Andrew B. Leiter, MD, PhD, and Charalabos Pothoulakis, MD
The AGA Council section "Regulatory Peptides, Cell Signaling, and Molecular Biology" (RPCMB) has broad interests in the basic mechanisms underlying digestive diseases and gastrointestinal physiology. From its origins in the study of gastrointestinal hormones, the section's membership has interests representing many areas of cutting-edge science including growth factors and stem cells, cellular differentiation in the GI track, epigenetics, mechanisms of receptor function, luminal chemosensing, intestinal inflammation, and mucosal injury and healing. Given the membership's strong interest in basic mechanisms, RPCMB has invited outside speakers who are leading scientists in their fields. Our section believes that it is an excellent opportunity to include the latest highly innovative scientific advances in the program at DDW before their incorporation into mainline digestive diseases research. This is clearly reflected in the quality of the speakers and cutting-edge research themes sponsored by RPCMB during DDW every year.
RPCMB will sponsor four invited speakers, three research fora, and four poster sessions as well as cosponsoring the Morton I. Grossman Lecture. We have an exciting lineup for DDW 2015.
State of the Art
Leonard Shultz from The Jackson Laboratory will be our State of the Art speaker (Saturday, May 16, 2015) . Dr Shultz has pioneered genetically engineered mice that carry humanized immune systems. Generation of mice customized to a specific patient's immune system may provide avatars for studying immune dysregulation occurring in cancer and autoimmune diseases. This approach may eventually lead to new therapies that are customized to individual patients.
